The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside

Journal of Bioenergetics and Biomembranes

Volumn 48, Issue 4, 2016, Pages 349-362

  Azevedo Silva, J ^a   Queiros O ^a,b   Baltazar, F ^a,c   Ulaszewski S ^d   Goffeau, A ^e   Ko, Y H ^f   Pedersen, P L ^g   Preto, A ^a   Casal, M ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF WROC AW   (Poland)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f UNIVERSITY OF MARYLAND   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 bromopyruvate; Cancer metabolism; Cancer therapy; Clinical studies; Monocarboxylate transporter; Tumor microenvironment

Indexed keywords

3 BROMOPYRUVATE; ANTINEOPLASTIC AGENT; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ALKYLATING AGENT; BROMOPYRUVATE; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BYSTANDER EFFECT; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL METABOLISM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IN VITRO STUDY; MULTIPLE CANCER; NONHUMAN; OXIDATIVE STRESS; REVIEW; TUMOR MICROENVIRONMENT; PROCEDURES; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS, ALKYLATING; ENZYME INHIBITORS; HUMANS; PYRUVATES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84979641440     PISSN: 0145479X     EISSN: 15736881     Source Type: Journal    
DOI: 10.1007/s10863-016-9670-z     Document Type: Review

References (119)

1. Amoêdo ND, Valencia JP, Rodrigues MF, Galina A, Rumjanek FD (2013) How does the metabolism of tumour cells differ from that of normal cells. Biosci Rep 33(6). doi:10.1042/BSR20130066
2. Azevedo-Silva J et al. (2015) The cytotoxicity of 3-Bromopyruvate in breast cancer cells depends on extracellular pH. Biochem J. doi:10.1042/BJ20140921
3. Baker JP, Rabin BR (1969) Effects of bromopyruvate on the control and catalytic properties of glutamate dehydrogenase. Eur J Biochem 11:154–159
4. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, Casal M (2014) Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 29:1511–1524
5. Barnard JP, Reynafarje B, Pedersen PL (1993) Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs. J Biol Chem 268:3654–3661
6. Bean JF, Qiu YY, Yu S, Clark S, Chu F, Madonna MB (2014) Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J Pediatr Surg 49:981–984; discussion 984 doi:10.1016/j.jpedsurg.2014.01.037
7. Bhardwaj V, Rizvi N, Lai MB, Lai JC, Bhushan A (2010) Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res 30:743–749
8. Birsoy K et al. (2013) MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 45:104–108. doi:10.1038/ng.2471
9. Bricker DK et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337(6090): 96–100. doi:10.1126/science.1218099
10. Buijs M et al. (2009) Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs 27:120–123. doi:10.1007/s10637-008-9145-0
11. Buijs M, Wijlemans JW, Kwak BK, Ota S, Geschwind JF (2013) Antiglycolytic therapy combined with an image-guided minimally invasive delivery strategy for the treatment of breast cancer J Vasc Interv Radiol 24:737–743 doi:10.1016/j.jvir.2013.01.013
12. Byrne FL et al. (2014) Metabolic vulnerabilities in endometrial cancer. Cancer Res 74:5832–5845. doi:10.1158/0008-5472.CAN-14-0254
13. Calviño E et al. (2014) Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation. J Pharmacol Exp Ther 348:324–335. doi:10.1124/jpet.113.206714
14. Cao X et al. (2008) Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol 62:985–994. doi:10.1007/s00280-008-0688-8
15. Cardaci S et al. (2012) Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res 72:4526–4536. doi:10.1158/0008-5472.CAN-12-1741
16. Chang GG, Hsu RY (1973) The substrate analog bromopyruvate as a substrate, an inhibitor and an alkylating agent of malic enzyme of pigeon liver. Biochem Biophys Res Commun 55:580–587
17. Chang JM, Chung JW, Jae HJ, Eh H, Son KR, Lee KC, Park JH (2007) Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model. Acad Radiol 14:85–92. doi:10.1016/j.acra.2006.09.059
18. Chapiro J et al. (2014) Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. Clin Cancer Res 20:6406–6417. doi:10.1158/1078-0432.CCR-14-1271
19. Chen Z, Zhang H, Lu W, Huang P (2009) Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787:553–560. doi:10.1016/j.bbabio.2009.03.003
20. Davidescu M et al. (2012) Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells. J Bioenerg Biomembr 44:51–60. doi:10.1007/s10863-012-9411-x
21. Davidescu M, Macchioni L, Scaramozzino G, Cristina Marchetti M, Migliorati G, Vitale R, Corcelli A, Roberti R, Castigli E, Corazzi L (2015) The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. Sci Rep 5:14343. doi:10.1038/srep14343
22. Dell’Antone P (2006) Inactivation of H + −vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. Life Sci 79:2049–2055. doi:10.1016/j.lfs.2006.06.043
23. Dell’Antone P (2009) Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Med Chem 5:491–496
24. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ (2012) The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 48:612–626. doi:10.1016/j.molcel.2012.08.033
25. Dylag M, Lis P, Niedzwiecka K, Ko YH, Pedersen PL, Goffeau A, Ulaszewski S (2013) 3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans. Biochem Biophys Res Commun 434:322–327. doi:10.1016/j.bbrc.2013.02.125
26. Ehrke E, Arend C, Dringen R (2014) 3-bromopyruvate inhibits glycolysis, depletes cellular glutathione, and compromises the viability of cultured primary rat astrocytes. J Neurosci Res. doi:10.1002/jnr.23474
27. El Sayed SM et al. (2012a) D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther 19:1–18. doi:10.1038/cgt.2011.59
28. El Sayed SM et al. (2012b) 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects. J Bioenerg Biomembr 44:61–79. doi:10.1007/s10863-012-9409-4
29. El Sayed SM et al. (2012c) D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects. J Bioenerg Biomembr 44:513–523. doi:10.1007/s10863-012-9455-y
30. El Sayed SM et al. (2014) Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. Chin J Cancer 33:356–364. doi:10.5732/cjc.013.10111
31. Galina A (2014) Mitochondria: 3-bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity. Int J Biochem Cell Biol 54:266–271. doi:10.1016/j.biocel.2014.05.013
32. Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, Prasad PD (2008) Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 10:193–199. doi:10.1208/s12248-008-9022-y
33. Ganapathy-Kanniappan S et al. (2010a) 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res 30:923–935
34. Ganapathy-Kanniappan S et al. (2010b) 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol 11:510–517
35. Ganapathy-Kanniappan S et al. (2012) Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology 262:834–845. doi:10.1148/radiol.11111569
36. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF (2013) Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 33:13–20
37. Garbutcheon-Singh KB, Harper BW, Myers S, Aldrich-Wright JR (2014) Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin Metallomics: integrated biometal science 6:126–131 doi:10.1039/c3mt00191a
38. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909–3913
39. Glick M, Biddle P, Jantzi J, Weaver S, Schirch D (2014) The antitumor agent 3-bromopyruvate has a short half-life at physiological conditions. Biochem Biophys Res Commun 452:170–173. doi:10.1016/j.bbrc.2014.08.066
40. Gong L, Wei Y, Yu X, Peng J, Leng X (2014) 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells: in vitro and in vivo findings. Anti Cancer Agents Med Chem 14:771–776
41. Gothe PO, Nyman PO (1972) Inactivation of human erythrocyte carbonic anhydrases by bromopyruvate. FEBS Lett 21:159–164
42. Guaragnella N, Giannattasio S, Moro L (2014) Mitochondrial dysfunction in cancer chemoresistance. Biochem Pharmacol 92(1):62–72. doi:10.1016/j.bcp.2014.07.027
43. Guo C, Liu S, Sun MZ (2013) Novel insight into the role of GAPDH playing in tumor Clinical & Transl Oncol: Official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 15:167–172 doi:10.1007/s12094-012-0924-x
44. Guo X, Zhang X, Xian S, Tan F, Lu Y, Wang T (2016) 3-Bromopyruvate and sodium citrate induce apoptosis in human gastric cancer cell line MGC-803 by inhibiting glycolysis and promoting mitochondria-regulated apoptosis pathway. Biochem Biophys Res Commun 475(1):37–43. doi:10.1016/j.bbrc.2016.04.151
45. Hajdu SI (2011) A note from history: landmarks in history of cancer, part 1. Cancer 117:1097–1102. doi:10.1002/cncr.25553
46. Herzig S et al. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. Science 337:93–96. doi:10.1126/science.1218530
47. Higashimura Y, Nakajima Y, Yamaji R, Harada N, Shibasaki F, Nakano Y, Inui H (2011) Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells. Arch Biochem Biophys 509:1–8. doi:10.1016/j.abb.2011.02.011
48. Hulleman E et al. (2009) Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113:2014–2021. doi:10.1182/blood-2008-05-157842
49. Hussien R, Brooks GA (2011) Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics 43(5):255–64. doi:10.1152/physiolgenomics.00177.2010
50. Icard P, Zhang XD, Lemoisson E, Louis MH, Allouche S, Lincet H, Poulain L (2012) Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies. J Bioenerg Biomembr 44:81–90. doi:10.1007/s10863-012-9415-6
51. Ihrlund LS, Hernlund E, Khan O, Shoshan MC (2008) 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Molecular Oncology 2:94–101. doi:10.1016/j.molonc.2008.01.003
52. Isayev O et al. (2014) Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget 5:5177–5189
53. Jardim-Messeder D, Moreira-Pacheco F (2016) 3-Bromopyruvic Acid Inhibits Tricarboxylic Acid Cycle and Glutaminolysis in HepG2 Cells. Anticancer Res 36(5):2233–2241
54. Kim W et al. (2007) Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6:2554–2562. doi:10.1158/1535-7163.MCT-07-0115
55. Kim JS et al. (2008) Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 40:607–618. doi:10.1007/s10863-008-9188-0
56. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91
57. Ko YH et al. (2004) Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269–275. doi:10.1016/j.bbrc.2004.09.047
58. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL (2012) A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 44:163–170. doi:10.1007/s10863-012-9417-4
59. Kunjithapatham R, Geschwind JF, Rao PP, Boronina TN, Cole RN, Ganapathy-Kanniappan S (2013) Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model. BMC Res Notes 6:277. doi:10.1186/1756-0500-6-277
60. Liu XH, Zheng XF, Wang YL (2009) Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J (Engl) 122:1681–1685
61. Liu Z, Zhang YY, Zhang QW, Zhao SR, CZ W, Cheng X, Jiang CC, Jiang ZW, Liu H (2014) 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway. Anti-Cancer Drugs 25(4):447–455. doi:10.1097/CAD.0000000000000081
62. Macchioni L et al. (2011) Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells J Bioenerg Biomembr 43:507–518 doi:10.1007/s10863-011-9375-2
63. Macchioni L, Davidescu M, Roberti R, Corazzi L (2014) The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria. J Bioenerg Biomembr 46(5):389–394. doi:10.1007/s10863-014-9577-5
64. Madhukar NS, Warmoes MO, Locasale JW (2015) Organization of enzyme concentration across the metabolic network in cancer cells. PLoS One 10:e0117131. doi:10.1371/journal.pone.0117131
65. Majkowska-Skrobek G et al. (2014) Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. Anti-cancer Drugs 25:673–682. doi:10.1097/CAD.0000000000000094
66. Marrache S, Dhar S (2015) The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate. Chem Sci 6(3):1832–1845. doi:10.1039/c4sc01963f
67. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777–4786. doi:10.1038/sj.onc.1209603
68. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer’s stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19(1):17–24. doi:10.1016/j.semcancer.2008.11.006
69. Matsumoto S et al. (2013) EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn Reson Med 69:1443–1450. doi:10.1002/mrm.24355
70. Matsushita K et al. (2012) Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1. J Pediatr Surg 47:1323–1330. doi:10.1016/j.jpedsurg.2011.12.007
71. Meloche HP (1967) Bromopyruvate inactivation of 2-keto-3-deoxy-6-phosphogluconic aldolase. I. Kinetic evidence for active site specificity. Biochemistry 6:2273–2280
72. Michelakis ED et al. (2010) Metabolic modulation of glioblastoma with dichloroacetate Sci Transl Med 2:31ra34 doi:10.1126/scitranslmed.3000677
73. Nakano A et al. (2011) Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 6:e27222. doi:10.1371/journal.pone.0027222
74. Nakano A et al. (2012) Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. J Bioenerg Biomembr 44:31–38. doi:10.1007/s10863-012-9412-9
75. Nilsson H, Lindgren D, Mandahl Forsberg A, Mulder H, Axelson H, Johansson ME (2015) Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate. Cell Death Dis 6:e1585. doi:10.1038/cddis.2014.545
76. Oronsky BT, Reid T, Knox SJ, Scicinski JJ (2012) The scarlet letter of alkylation: a mini review of selective alkylating agents. Transl Oncol 5:226–229
77. Ota S, Geschwind JF, Buijs M, Wijlemans JW, Kwak BK, Ganapathy-Kanniappan S (2013) Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol 8:145–151. doi:10.1007/s11523-013-0273-x
78. Parks SK, Chiche J, Pouyssegur J (2013) Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 13:611–623. doi:10.1038/nrc3579
79. Pedersen PL (2007) Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the "Warburg Effect", i.e., Elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(3):211–222
80. Pedersen PL (2012a) 3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. J Bioenerg Biomembr 44(1):1–6. doi:10.1007/s10863-012-9425-4
81. Pedersen PL (2012b) Mitochondria in relation to cancer metastasis: introduction to a mini-review series. J Bioenerg Biomembr 44(6):615–617. doi:10.1007/s10863-012-9470-z
82. Pereira da Silva AP et al. (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417:717–726. doi:10.1042/BJ20080805
83. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F (2012) Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 44:127–139. doi:10.1007/s10863-012-9428-1
84. Qin JZ, Xin H, Nickoloff BJ (2010) 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun 396:495–500. doi:10.1016/j.bbrc.2010.04.126
85. Queiros O et al. (2012) Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr 44:141–153. doi:10.1007/s10863-012-9418-3
86. Rodrigues-Ferreira C, da Silva AP, Galina A (2012) Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase. J Bioenerg Biomembr 44:39–49. doi:10.1007/s10863-012-9413-8
87. Sadowska-Bartosz I, Bartosz G (2013) Effect of 3-bromopyruvic acid on human erythrocyte antioxidant defense system. Cell Biol Int 37:1285–1290. doi:10.1002/cbin.10160
88. Sadowska-Bartosz I, Soszynski M, Ulaszewski S, Ko Y, Bartosz G (2014) Transport of 3-bromopyruvate across the human erythrocyte membrane. Cell Mol Biol Lett 19:201–214. doi:10.2478/s11658-014-0189-1
89. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T (2000) Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95:3214–3218
90. Sanchez-Arago M, Cuezva JM (2011) The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 9(19). doi:10.1186/1479-5876-9-19
91. Schaefer NG, Geschwind JF, Engles J, Buchanan JW, Wahl RL (2012) Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. Transl Res 159:51–57. doi:10.1016/j.trsl.2011.08.008
92. Shoshan MC (2012) 3-bromopyruvate: targets and outcomes. J Bioenerg Biomembr 44:7–15. doi:10.1007/s10863-012-9419-2
93. Sonveaux P et al. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118(12):3930–3942. doi:10.1172/JCI36843
94. Staub M, Denes G (1967) A kinetic study on the inactivation of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase by bromopyruvate. Biochim Biophys Acta 139:519–521
95. Szablewski L (2013) Expression of glucose transporters in cancers. Biochim Biophys Acta 1835:164–169. doi:10.1016/j.bbcan.2012.12.004
96. Tang Z et al. (2012) Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr 44:117–125. doi:10.1007/s10863-012-9420-9
97. Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, Ganapathy V (2009) Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115:4655–4666. doi:10.1002/cncr.24532
98. Thornalley PJ, Rabbani N (2011) Glyoxalase in tumourigenesis and multidrug resistance. Sem Cell Dev Biol 22:318–325. doi:10.1016/j.semcdb.2011.02.006
99. Tristan C, Shahani N, Sedlak TW, Sawa A (2011) The diverse functions of GAPDH: views from different subcellular compartments. Cell Signal 23:317–323. doi:10.1016/j.cellsig.2010.08.003
100. Tsai HJ, Wilson JE (1996) Functional organization of mammalian hexokinases: both N- and C-terminal halves of the rat type II isozyme possess catalytic sites. Arch Biochem Biophys 329:17–23. doi:10.1006/abbi.1996.0186
101. Valenti D, Vacca RA, de Bari L (2015) 3-Bromopyruvate induces rapid human prostate cancer cell death by affecting cell energy metabolism, GSH pool and the glyoxalase system. J Bioenerg Biomembr 47:493–506 doi:10.1997/s10863-015-9631-y
102. Vali M et al. (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18:95–101. doi:10.1016/j.jvir.2006.10.019
103. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033. doi:10.1126/science.1160809
104. Verhoeven HA, van Griensven LJ (2012) Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis. J Bioenerg Biomembr 44:91–99. doi:10.1007/s10863-012-9414-7
105. Vossen JA, Buijs M, Syed L, Kutiyanwala F, Kutiyanwala M, Geschwind JF, Vali M (2008) Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp metastasis 25:811–817. doi:10.1007/s10585-008-9195-x
106. Warburg O (1956) On respiratory impairment in cancer cells, vol 124. Science, pp. 269–270
107. Wicks RT et al. (2015) Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro-Oncology 17:70–80. doi:10.1093/neuonc/nou143
108. Wintzell M, Lofstedt L, Johansson J, Pedersen AB, Fuxe J, Shoshan M (2012) Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther 13:1454–1462. doi:10.4161/cbt.22007
109. Wu L et al. (2014) The reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cells. PLoS One 9:e112132 doi:10.1371/journal.pone.0112132
110. Xian SL, Cao W, Zhang XD, Lu YF (2014) Inhibitory effects of 3-bromopyruvate on human gastric cancer implant tumors in nude mice Asian Pac. J Cancer Prev 15:3175–3178
111. Xiao H, Li S, Zhang D, Liu T, Yu M, Wang F (2013) Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells. Oncol Rep 29:329–334. doi:10.3892/or.2012.2085
112. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P (2005) Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19:2153–2158. doi:10.1038/sj.leu.2403968
113. Yoong SL et al. (2014) Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials 35:748–759. doi:10.1016/j.biomaterials.2013.09.036
114. Yu SJ et al. (2011) Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin 32:912–920. doi:10.1038/aps.2011.24
115. Yu SJ et al. (2012) Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr 44:101–115. doi:10.1007/s10863-012-9416-5
116. Yun J et al. (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325:1555–1559. doi:10.1126/science.1174229
117. Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y, You M (2012) Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res (Phila) 5:717–725. doi:10.1158/1940-6207.CAPR-11-0338
118. Zhang Q et al. (2014) Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer 5:100–112
119. Zhou Y et al. (2012) Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 72:304–314. doi:10.1158/0008-5472.CAN-11-1674